SecBot SecBot
8-K ·Filed Aug 19, 2026

ETST

Earth Science Tech, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed2mo ago SEC0001493152-26-039138
8-K material event: Items 2.01
Actionable Insight • Neutral

This is a small, related-party acquisition with no disclosed financial terms, making it a low-impact event. Monitor future quarterly filings for any measurable margin improvement or revenue contribution from the veterinary expansion. The related-party nature warrants scrutiny of governance, but the immateriality limits immediate trading implications.

DirectionNeutral
Confidencemedium
Horizonweeks
Latest settled — T+20d
ETST ▼ -15.89% at T+20d
NEUTRAL call -15.89% · α vs SPY -14.37% · entry $0.1070 → $0.0900
Next anchor: T+60d in 16d
Latest observation: T+46 +48.42% FF3 residual α
Entry = T+0 close
Aug 19, 2026
via day close
T+1d
+14.45%
call +14.45% · α +15.29%
$0.1225
settled 2mo ago
T+5d
-11.21%
call -11.21% · α -10.83%
$0.0950
settled 2mo ago
T+20d
-15.89%
call -15.89% · α -14.37%
$0.0900
settled 6w ago
T+60d
Pending
in 16d

Price Chart

Loading chart...

Executive Summary

Earth Science Tech, Inc. (ETST) acquired Zoolzy LLC, a wholesale distributor of active pharmaceutical ingredients, from its own COO and board member Mario G. Tabraue in a related-party transaction. The terms were not disclosed as immaterial. The acquisition is intended to internalize API procurement for margin expansion and to enable a strategic entry into the veterinary market, but no financial details or guidance were provided to quantify the impact.

Key Facts

  • ETST acquired Zoolzy LLC, a Florida-based wholesale distributor of APIs and finished FDA-approved prescription products.
  • The acquisition was a related-party transaction from COO and board member Mario G. Tabraue.
  • Terms were not disclosed due to being immaterial.
  • The deal closed on August 17, 2026, and was announced via press release on August 19, 2026.
  • ETST plans to use Zoolzy to internalize API procurement for its compounding pharmacies and expand into the veterinary market.

Financial Impact

Terms undisclosed and described as immaterial; no financial impact quantified in the filing.

Risk Factors

  • Related-party transaction raises governance concerns despite independent board approval.
  • No financial guidance or deal terms provided, making it impossible to assess accretion or dilution.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-039138
Exhibit: ex99-1.htm0001493152-26-039138
Document: 0001493152-26-039138-index-headers.html0001493152-26-039138
Document: 0001493152-26-039138-index.html0001493152-26-039138
Document: 0001493152-26-039138.txt0001493152-26-039138
6 reports for ETST
Performance horizon
Filters
Rows
Reports for ETST — sortable, filterable
TypeNow
Oct 26, 2026
today
8-K
NEUTRAL ★ 3/10
$0.0899awaiting T+20—$0.0947 (+5.34%)
Sep 1, 2026
7w ago
8-K
NEUTRAL ★ 4/10
$0.0880 $0.0911▲ +3.52%▲ +2.34%$0.0947 (+7.61%)
Aug 19, 2026
9w ago
8-K
NEUTRAL ★ 3/10
$0.1070 $0.0900▼ −15.89%▼ −14.37%$0.0947 (−11.50%)
Aug 12, 2026
10w ago
8-K
NEUTRAL ★ 3/10
$0.0921 $0.0900▼ −2.28%▼ −0.53%$0.0947 (+2.82%)
Aug 7, 2026
11w ago
8-K
NEUTRAL ★ 4/10
$0.0979 $0.0900▼ −8.07%▼ −7.67%$0.0947 (−3.27%)
Jun 18, 2026
18w ago
8-K
NEUTRAL ★ 4/10
$0.1760 $0.1400▼ −20.45%▼ −19.99%$0.0947 (−46.19%)
Showing 6 of 6

US Market Status

Market Open — Closes in 3h 59m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 19, 2026